Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Japanese Healthcare Q&A (6)
March 15, 2004
- Yamanouchi to Promote Stasis in Patients with Mild Diabetes
March 15, 2004
- Fujisawa's R&D Pipeline Updated
March 15, 2004
- Banyu to Focus More Resources on Marketing of Fosamac
March 15, 2004
- New GL for Cerebral Apoplexy Released
March 15, 2004
- BUSINESS NEWS IN BRIEF
March 8, 2004
- PFSB to Revise GL on Information Disclosure
March 8, 2004
- REGULATORY NEWS IN BRIEF
March 8, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 8, 2004
- INF b-1b Effective against Multiple Sclerosis: Nihon Schering Seminar
March 8, 2004
- Annual Business Results
March 8, 2004
- 1st 3 Qtrs Business Results
March 8, 2004
- Lower Cholesterol Reduces Vascular Disease Risk: Banyu Symposium
March 8, 2004
- Novo Nordisk to Introduce New MR Training System in April
March 8, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 8, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 8, 2004
- Major Purchasers Taking Advantage of Consumption Tax Labeling Change
March 8, 2004
- Aiming to Strengthen R&D Capability, Independent Sales Forces Abroad: Yamanouchi, Fujisawa
March 8, 2004
- OTC NEWS IN BRIEF
March 8, 2004
- Allegra, Alesion Are Doctors' 1st Choice Prescriptions for Pollinosis: PJ, So-net M3 Survey
March 8, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…